ABSTRACT

CYCLOALKYL-[4-(DIFLUOROPHENYL)-OXAZOL-5-YL]-TRIAZOLO-PYRIDINES

The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions
containing them and to their medicinal use. The compounds of the present invention are
potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of
inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or
heart attack, autoimmune diseases and other disorders.